On October 5, 2022 OncoNano Medicine, Inc. reported it will be presenting data on two development candidates, as well as its ON-BOARD delivery platform, at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC) (Free SITC Whitepaper), taking place November 8-12, 2022 in Boston, Massachusetts (Press release, OncoNano Medicine, OCT 5, 2022, View Source [SID1234621722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An oral and poster presentation by Dr. Qiang Feng detail new pre-clinical data for ONM-405, an IL-2-Fc construct formulated with OncoNano’s proprietary ON-BOARD polymeric-micelle delivery system. OncoNano’s lead clinical candidate, pegsitacianine, currently in Phase 2 clinical trials, is formulated with ON-BOARD. The ON-BOARD platform is designed to carry oncology intervention payloads systemically to the tumor microenvironment, minimizing systemic exposure and toxicity.

OncoNano will also present a poster detailing data from studies involving the use of the ON-BOARD platform for encapsulation and delivery of bispecific T cell engagers. In addition, a poster will feature new preclinical data of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications.